Form 8-K - Current report:
SEC Accession No. 0001437749-25-012917
Filing Date
2025-04-24
Accepted
2025-04-24 14:45:50
Documents
15
Period of Report
2025-04-24
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K inbp20250422_8k.htm   iXBRL 8-K 36078
2 EXHIBIT 16.1 LETTER FROM MARCUM LLP ex_805481.htm EX-16.1 2932
  Complete submission text file 0001437749-25-012917.txt   167754

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inbp-20250424.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20250424_def.xml EX-101.DEF 10353
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20250424_lab.xml EX-101.LAB 13836
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20250424_pre.xml EX-101.PRE 10348
17 EXTRACTED XBRL INSTANCE DOCUMENT inbp20250422_8k_htm.xml XML 2561
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31668 | Film No.: 25866690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)